Krystexxa OverviewPegloticase (trade name Krystexxa) is a medication for the treatment of severe, treatment-refractory, chronic gout. It is a third line treatment in those in whom other treatments are not tolerated. The drug is administered by infusion intravenously. It was developed by Savient Pharmaceuticals. In September 2010, the FDA approved pegloticase for marketing in the United States after two clinical trials demonstrated the drug lowered uric a...
Read more Krystexxa Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Pegloticase
Recent Krystexxa Forums:Be the first to start a discussion about this drug.
Possible Dosages for this and Related Drugs:
- Injection: 8mg
NDC Database Records for Krystexxa: (3 results)Sorted by National Drug Code
- 54396-801 Krystexxa 8 mg/ml Intravenous Injection, Solution by Savient Pharmaceuticals, Inc.
- 60809-801 Krystexxa 8 mg/ml Intravenous Injection, Solution by Crealta Pharmaceuticals LLC
- 75987-080 Krystexxa 8 mg/ml Intravenous Injection, Solution by Horizon Pharma Inc.